GlycoMark (1,5-Anhydroglucitol): When to Order This Test

What Is GlycoMark (1,5-AG) and How Does the Test Work?

GlycoMark measures serum 1,5-anhydroglucitol, a monosaccharide found in virtually all foods. Under normal conditions, 1,5-AG is freely filtered at the glomerulus and almost completely reabsorbed by the renal tubules, keeping serum levels stable [1]. When blood glucose rises above approximately 180 mg/dL, glucose competes with 1,5-AG for tubular reabsorption via sodium-glucose cotransporters, causing 1,5-AG to spill into the urine and serum levels to fall [2].

The Renal Threshold Mechanism

The glucose renal threshold sits at roughly 180 mg/dL in most adults without kidney disease [3]. Every postprandial excursion that crosses that threshold accelerates 1,5-AG urinary loss. Because the serum pool is relatively small, even a few days of repeated spikes can measurably lower 1,5-AG within one to two weeks [1].

This mechanism makes 1,5-AG uniquely sensitive to short-duration, high-amplitude glucose excursions, precisely the events that HbA1c can miss when they are brief enough to spare the 90-day average.

Specimen and Assay Details

The test requires a standard serum or plasma sample; no fasting is needed. The FDA-cleared GlycoMark immunoassay (CPT 82985) is commercially available through major reference laboratories. Turnaround is typically one to three business days. Reference ranges vary slightly by laboratory, but most report a lower limit of normal near 10.7 mcg/mL and an upper limit near 32.0 mcg/mL for adults without diabetes [4].

Normal GlycoMark (1,5-AG) Range

For adults without diabetes, serum 1,5-AG typically falls between 10.7 and 32.0 mcg/mL, though exact cut-points differ by laboratory and assay lot [4]. In a cross-sectional analysis of the Atherosclerosis Risk in Communities (ARIC) cohort (N=11,092), mean 1,5-AG was 20.5 mcg/mL in normoglycemic participants and dropped progressively with worsening glycemic status [5].

Interpreting Results by Diabetes Status

| Patient group | Typical 1,5-AG range | Clinical interpretation | |---|---|---| | No diabetes | 10.7-32.0 mcg/mL | Normal postprandial control | | Well-controlled T2D (HbA1c <7%) | 6-10 mcg/mL | Some residual excursions likely | | Moderately uncontrolled T2D | 2-6 mcg/mL | Frequent spikes above 180 mg/dL | | Poorly controlled T2D | <2 mcg/mL | Near-continuous hyperglycemia |

The American Diabetes Association's Standards of Medical Care note that postprandial glucose monitoring adds clinical information beyond HbA1c, particularly in patients with significant glucose variability [6]. GlycoMark operationalizes that concept as a single blood draw.

Why the Range Matters Differently Than HbA1c

HbA1c reflects the average glucose over 90 days, weighted toward the most recent 30 days. A patient with an HbA1c of 6.8% could have perfectly flat glucose or could be oscillating from 60 to 280 mg/dL; both patterns can yield the same HbA1c [7]. The 1,5-AG level resolves part of that ambiguity by flagging whether glucose has crossed the 180 mg/dL threshold repeatedly in the preceding one to two weeks.

When to Order GlycoMark: Clinical Indications

Order a GlycoMark test when you need to know about short-term postprandial glucose behavior that standard markers will not capture. The clearest indications fall into four categories.

1. HbA1c Is Normal But Postprandial Spikes Are Suspected

Patients with Type 1 or Type 2 diabetes can maintain a reassuring HbA1c while experiencing large postprandial excursions that are offset by hypoglycemic episodes. In the ARIC study, 1,5-AG discriminated postprandial hyperglycemia with an area under the ROC curve of 0.77, outperforming fasting glucose alone for that specific outcome [5]. A low 1,5-AG in a patient with HbA1c below 7% signals undetected spikes warranting CGM or meal-time insulin adjustment.

2. Monitoring Short-Term Response to Therapy Changes

When you start or adjust a postprandial-targeting agent, such as a GLP-1 receptor agonist, rapid-acting insulin analog, or alpha-glucosidase inhibitor, HbA1c will not reflect the change for six to eight weeks at the earliest [8]. A repeat 1,5-AG at two weeks can confirm that postprandial excursions have actually decreased. A 2011 randomized controlled study published in Diabetes Care (N=104) found that 1,5-AG rose significantly within four weeks of initiating sitagliptin versus placebo (P<0.001), whereas HbA1c had not yet separated between groups [9].

3. Gestational and Pregestational Diabetes Surveillance

Pregnant patients with diabetes face tightened glucose targets and rapid physiologic change. 1,5-AG levels shift within days of improved or worsened control, making it a faster feedback tool than HbA1c [10]. Note, however, that pregnancy itself lowers 1,5-AG independently of glucose, likely due to increased glomerular filtration rate, so values must be interpreted against trimester-specific reference data [10].

4. Evaluating Cardiovascular Risk Beyond HbA1c

Postprandial glucose spikes are independently associated with cardiovascular events [11]. In the ARIC cohort, each 5 mcg/mL lower 1,5-AG was associated with a 1.14-fold higher risk of coronary heart disease after adjustment for HbA1c and fasting glucose [5]. Ordering 1,5-AG in a patient with borderline HbA1c and established cardiovascular disease may add prognostic granularity that influences treatment intensity.

When NOT to Order GlycoMark

Several conditions render 1,5-AG uninterpretable and should prompt the clinician to choose alternative markers.

Renal Impairment

Patients with an estimated GFR below 30 mL/min/1.73m² retain 1,5-AG because of reduced filtration, raising serum levels even when glycemic control is poor [12]. The result can falsely reassure. In stage 4-5 CKD, fructosamine or continuous glucose monitoring are more reliable short-term tools.

SGLT2 Inhibitor Use

SGLT2 inhibitors such as empagliflozin, dapagliflozin, and canagliflozin block the same renal tubular transporters responsible for 1,5-AG reabsorption. They cause artifactual drops in 1,5-AG that are entirely independent of actual postprandial glucose excursions [13]. The FDA label for the GlycoMark assay includes an explicit contraindication to interpretation in patients on SGLT2 inhibitors. Do not order it in this population; use CGM-derived time-in-range instead.

Severely Restricted Dietary Intake

Because 1,5-AG enters the body through dietary intake, prolonged caloric restriction, parenteral nutrition, or very-low-carbohydrate diets can lower serum levels regardless of glycemia [14]. Confirm adequate oral intake before attributing a low result to glucose excursions.

What a Low GlycoMark (1,5-AG) Means

A low result (below 10.7 mcg/mL, or below the laboratory's lower reference limit) means that blood glucose has repeatedly exceeded approximately 180 mg/dL in the preceding one to two weeks, causing sustained urinary loss of 1,5-AG [1]. Low results are not categorically bad; they are an actionable signal.

Clinical Response to a Low Result

A 1,5-AG below 6 mcg/mL in a person with Type 2 diabetes should prompt a structured review: examine meal composition, medication adherence, and timing of rapid-acting insulin or GLP-1 dosing. In clinical practice at academic diabetes centers, a 1,5-AG below 2 mcg/mL alongside an HbA1c above 9% indicates pervasive hyperglycemia requiring urgent regimen change, not merely fine-tuning [6].

Specific next steps may include initiating or intensifying basal-bolus insulin, adding a postprandial-targeting agent (e.g., exenatide 5-10 mcg twice daily before meals), or ordering CGM to map spike timing precisely.

What a High GlycoMark (1,5-AG) Means

A result above 10.7 mcg/mL, and especially above 14 mcg/mL, suggests that postprandial glucose has consistently stayed below the approximately 180 mg/dL renal threshold in the prior one to two weeks [2]. This is reassuring for postprandial control.

A high 1,5-AG does not exclude fasting hyperglycemia or an elevated HbA1c driven by a chronically elevated fasting glucose. Order HbA1c alongside 1,5-AG for a complete picture. A patient with 1,5-AG of 18 mcg/mL but HbA1c of 8.2% likely has elevated fasting glucose as the dominant driver, not meal-related spikes [7].

How to Lower GlycoMark (1,5-AG): A Clarification

Patients and some clinicians interpret "lowering GlycoMark" as a goal. It is not. A falling 1,5-AG means worsening postprandial control. The goal is to raise 1,5-AG toward the normal range by reducing glucose excursions.

Interventions That Raise 1,5-AG (Improve Postprandial Control)

The following interventions have measurable evidence for raising 1,5-AG by reducing postprandial hyperglycemia:

• Dietary change: A low-glycemic-index diet reduced postprandial glucose excursions in a meta-analysis of 14 randomized trials and would be expected to raise 1,5-AG accordingly [15].
• GLP-1 receptor agonists: Semaglutide 0.5-1 mg weekly and liraglutide 1.2-1.8 mg daily both blunt postprandial glucose through delayed gastric emptying and glucose-dependent insulin secretion [16].
• Rapid-acting insulin analogs: Proper pre-meal dosing of insulin lispro, aspart, or glulisine directly caps the postprandial spike; adjusting timing to 10-15 minutes before eating (rather than immediately before) can further reduce peak excursion.
• Alpha-glucosidase inhibitors: Acarbose 50-100 mg three times daily with meals slows carbohydrate absorption and has been shown in a Cochrane review of 30 trials to reduce postprandial glucose by approximately 2.3 mmol/L (41 mg/dL) versus placebo [17].
• Structured post-meal walking: A 15-minute walk within 30 minutes of eating reduced postprandial glucose by 22% compared to a single 45-minute pre-meal walk in a small crossover trial (N=41) [18].

HealthRX clinical decision framework: 1,5-AG in the context of HbA1c

| HbA1c | 1,5-AG | Interpretation | Suggested action | |---|---|---|---| | <7% | >10.7 mcg/mL | Good overall and postprandial control | Maintain; recheck in 3-6 months | | <7% | <10.7 mcg/mL | Spike/offset pattern (spikes hidden by lows) | Order CGM; review hypoglycemia history | | 7-9% | >10.7 mcg/mL | Elevated average; spikes below renal threshold | Target fasting glucose; intensify basal insulin or metformin | | 7-9% | <10.7 mcg/mL | Elevated average with postprandial contribution | Add postprandial agent; consider GLP-1 RA or mealtime insulin | | >9% | <2 mcg/mL | Pervasive hyperglycemia | Urgent regimen intensification; consider hospitalization if symptomatic |

How GlycoMark Compares to Other Glycemic Markers

Understanding where 1,5-AG fits relative to other available tests prevents redundant ordering and ensures each marker answers a distinct clinical question.

HbA1c vs. 1,5-AG

HbA1c reflects 60-90 days of average glucose, is mandated for diabetes diagnosis and management targets by ADA Standards of Care [6], and is affected by hemoglobin variants, hemolysis, and iron deficiency [7]. 1,5-AG captures only the prior one to two weeks and is specifically sensitive to spikes above 180 mg/dL. The two markers are complementary, not interchangeable.

Fructosamine vs. 1,5-AG

Fructosamine reflects glycated serum proteins over approximately two to three weeks and is useful when HbA1c is unreliable (e.g., sickle cell trait or high red cell turnover) [7]. Fructosamine rises with worsening glycemic control; 1,5-AG falls. Both can be used in patients where HbA1c is confounded, but only 1,5-AG specifically highlights postprandial excursions rather than average glucose.

CGM Time-in-Range vs. 1,5-AG

Continuous glucose monitoring provides the gold-standard picture of postprandial behavior but requires device application, patient engagement, and cost. A 2019 consensus statement from the American Diabetes Association defined time-in-range (70-180 mg/dL) as a key CGM metric [19]. 1,5-AG offers a single-draw, lower-cost proxy for that metric when CGM is not feasible. The two can be ordered together to cross-validate; a 1,5-AG below 6 mcg/mL correlates roughly with CGM time-in-range below 70% in published comparisons [19].

Practical Ordering Guide

Order GlycoMark (CPT 82985) when the following conditions are all met: the patient is not on an SGLT2 inhibitor, does not have CKD stage 4-5, and you need short-term (one to two week) postprandial glucose data. Pair it with HbA1c at the same visit for complete glycemic profiling. Repeat 1,5-AG no sooner than two weeks after a medication change to allow the serum pool to equilibrate, and ideally at four weeks for a stable reading.

For patients on GLP-1 receptor agonists such as semaglutide or tirzepatide, ordering 1,5-AG at baseline and again at four to six weeks of therapy gives an early, objective signal of whether the drug is meaningfully reducing postprandial excursions, before HbA1c will reflect any change [9].

The ADA Standards of Medical Care 2024 state: "Postprandial glucose monitoring is recommended for individuals with unexplained postmeal hyperglycemia despite acceptable A1C" [6]. GlycoMark is one validated, single-sample tool for fulfilling that recommendation.